Hypertension’s 15-Year Drought Is Finally Breaking

Key Takeaway: After more than fifteen years without a new class of blood pressure-lowering drugs, the field of hypertension is undergoing a tectonic shift. As the updated 2025 AHA/ACC guidelines push systolic blood pressure targets below 130 mm Hg—and even below 120 mm Hg where possible—a wave of innovative drugs targeting entirely new biological pathways offers hope for millions of patients unable to reach these ambitious goals with current therapies.

A Dormant Field Reawakens

For fifteen years, the pharmacological arsenal against high blood pressure remained virtually unchanged. Five core drug classes shouldered nearly the entire therapeutic burden: ACE inhibitors, ARBs, calcium channel blockers, thiazide diuretics, and beta-blockers. Clinicians adjusted doses and combinations, but the underlying chemistry of treatment was all but frozen in time. Meanwhile, nearly half of hypertensive adults in the United States were failing to meet even modest blood pressure targets^[2]. Now, after years of stagnation, two powerful currents are converging: compelling evidence mandating more aggressive targets and a genuine wave of innovative therapies acting on pathways untouched by any existing drug. The result is nothing short of a revolution in how we approach and treat the world’s leading modifiable risk factor for death.

What This Review Reveals

A comprehensive 2025 review synthesizes evidence from recent landmark trials supporting intensive treatment aimed at lowering systolic blood pressure to below 120 mm Hg^[1]. The review was published on the heels of the updated 2025 AHA/ACC clinical practice guideline, which adopted a universal target of below 130/80 mm Hg for nearly all adults with hypertension and openly encouraged pushing systolic pressure below 120 mm Hg when it can be done safely. This represents a significant departure from the more conservative thresholds that dominated practice for years, during which many clinicians were comfortable tolerating systolic readings in the 140s.

Two other major studies have been published that support this view. The BPROAD trial explicitly supports intensive systolic blood pressure targets below 120 mm Hg in patients with type 2 diabetes at high cardiovascular risk, while the ESPRIT trial extends randomized evidence to a broader high-risk population that includes both diabetes and a history of prior stroke. ^[9][10] The mortality reduction in the ESPRIT trial is supported by reviews and meta-analyses; the ESPRIT trial reported more cardiovascular and all-cause deaths than the BPROAD trial. ^[11][12]

But the review goes beyond targets. It catalogs a new class of therapies that are ending the 15-year drought in novel antihypertensive mechanisms. These include drugs that block endothelin receptors, directly inhibit aldosterone synthesis, and silence the liver’s production of angiotensinogen, the precursor protein at the very top of the renin-angiotensin cascade. Device-based therapies, particularly renal denervation, are making a comeback with improved technology and more robust sham-controlled trial data. Perhaps most importantly, the review frames the future of hypertension management not as a continuation of the usual stepped-care algorithm, but as a shift toward phenotype-driven, precision therapy.

Why the Body Resists and How New Drugs Break Through

To understand why these new therapies matter, one must grasp how blood pressure is regulated and why current drugs sometimes fail. Blood pressure is a product of cardiac output and peripheral vascular resistance, governed by a complex network of hormonal, neural, and renal systems^[3]. The renin-angiotensin-aldosterone system (RAAS) is the best-known axis: the kidneys release renin, which converts angiotensinogen from the liver into angiotensin I; this is then converted to angiotensin II, which is both a potent vasoconstrictor and a stimulus for aldosterone release from the adrenal glands. Current drugs block this cascade at various points, but compensatory mechanisms often kick in, blunting their effects.

The new therapies attack from angles the body hasn’t yet learned to compensate for. For instance, agents targeting hepatic angiotensinogen use RNA interference or antisense technology to turn down the liver’s production of this precursor protein. This essentially cuts off the RAAS at its source rather than blocking downstream receptors^[4]. Early clinical data show these agents can provide durable blood pressure reductions lasting for weeks or even months after a single injection—a transformative possibility for patients who struggle with daily medication adherence. This is a significant development, as initial findings support the fundamental claim: suppression of hepatic angiotensinogen, particularly with zilebesiran, can provide sustained blood pressure reduction after a single injection. The unresolved question is whether this durable upstream RAAS blockade improves long-term clinical outcomes and remains safe in broader patient populations.^[13] This is under investigation, and there is still a long way to go.

Aldosterone synthase inhibitors are another game-changer. Aldosterone drives sodium retention and vascular fibrosis, and in a significant subset of hypertensive patients—especially those with resistant hypertension—aldosterone excess is the dominant mechanism^[5]. Unlike spironolactone, which blocks the mineralocorticoid receptor but carries side effects like gynecomastia and hyperkalemia, these new agents inhibit the enzyme that produces aldosterone in the first place, offering a cleaner pharmacological profile.

Endothelin receptor antagonists target a potent vasoconstrictor peptide produced by the blood vessel wall itself. While endothelin-1 has long been associated with pulmonary arterial hypertension, newer selective antagonists are being developed specifically for systemic hypertension and its resistant forms, where standard therapies fall short^[6].

Then there is renal denervation: a catheter-based procedure that ablates the sympathetic nerves running along the renal arteries. After initial disappointment from the SYMPLICITY HTN-3 trial, improved technology and rigorous sham-controlled trials like SPYRAL HTN-ON MED and RADIANCE-HTN TRIO have demonstrated significant blood pressure reductions, reigniting interest in the approach^[7].

What These Advances Mean for Tomorrow’s Patients

The practical implications are profound. The new guideline targets mean that a patient whose blood pressure was previously 135/82 and was told this was ‘acceptable’ may now be counseled that further reduction is necessary. For the roughly 10-12% of hypertensive patients whose blood pressure remains uncontrolled on three or more medications—the group with so-called ‘resistant hypertension’—these emerging drug classes offer real hope where little existed before.

The shift to phenotype-driven therapy is equally significant. Rather than following a one-size-fits-all algorithm, clinicians may soon be able to profile a patient’s dominant pathophysiology—sympathetic overdrive, aldosterone excess, endothelin-mediated vascular stiffness—and match the therapy accordingly. This mirrors the precision medicine approach that has already transformed oncology and is long overdue in cardiovascular care.

A Note of Caution

This review synthesizes evidence rather than presenting a single randomized trial, and the new agents described are in various stages of clinical development. Long-term safety and cardiovascular outcomes data are still being collected for many of these therapies. Intensive blood pressure lowering also carries real risks, including hypotension, dizziness, acute kidney injury, and falls in older adults, which must be weighed against the cardiovascular benefits demonstrated in trials like SPRINT^[8]. A single review, no matter how comprehensive, does not change everything overnight. But the trajectory is clear: lower targets, smarter drugs, and a more personalized approach to a condition that silently causes more strokes, heart attacks, and kidney failure than any other modifiable risk factor on earth.

Scientific Sources

1. Agarwal R. Hypertension at an Inflection Point: Aggressive Targets Meet Novel Mechanisms for Cardiovascular Prevention. Journal of the American College of Cardiology. 2026;88(3):373-388. PubMed: https://pubmed.ncbi.nlm.nih.gov/42307497/
2. Muntner P, et al. Blood Pressure Control Among US Adults, 2009 to 2018. Hypertension. 2020. DOI: 10.1161/HYPERTENSIONAHA.122.19222
3. Guyton AC, et al. Arterial Pressure Regulation: Overriding Dominance of the Kidneys in Long-Term Regulation and in Hypertension. Am J Med. 1972. DOI: 10.1016/0002-9343(72)90050-2
4. Desai AS, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023. DOI: 10.1056/NEJMoa2208391
5. Barrera-Chimal J, et al. Aldosterone synthase inhibition: a novel bullet to fight cardiovascular-kidney-metabolic syndrome. J Mol Endocrinol. 2025. DOI: 10.1530/JME-25-0047
6. Barton M, et al. Endothelin: 30 Years From Discovery to Therapy. Hypertension. 2019. DOI: 10.1161/HYPERTENSIONAHA.119.12105
7. Azizi M, et al. Ultrasound Renal Denervation for Hypertension Resistant to a Triple Medication Pill (RADIANCE-HTN TRIO). Lancet. 2021. DOI: 10.1016/S0140-6736(21)00788-1
8. Wright JT Jr, et al. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med. 2015. DOI: 10.1056/NEJMoa1511939
9. Bi Y, et al. Intensive Blood-Pressure Control in Patients with Type 2 Diabetes..” The New England journal of medicine. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2412006
10. Liu J, et al. Lowering systolic blood pressure to less than 120 mm Hg versus less than 140 mm Hg in patients with high cardiovascular risk with and without diabetes or previous stroke: an open-label, blinded-outcome, randomised trial. Lancet. 2024. DOI: 10.1016/S0140-6736(24)01028-6
11. Kreutz R, et al. Lowering of systolic blood pressure with ESPRIT along the BPROAD: the lower the better? Clin Hypertens. 2025. DOI: 10.5646/ch.2025.31.e20
12. Bergmann F, et al. Systolic blood pressure targets below 120 mm Hg are associated with reduced mortality: A meta‐analysis. J Intern Med. 2025. DOI: 10.1111/joim.20078
13. Bakris G, et al. RNA Interference With Zilebesiran for Mild to Moderate Hypertension: The KARDIA-1 Randomized Clinical Trial. JAMA. 2024. DOI: 10.1001/jama.2024.0728